RAPT Therapeutics, Inc. (NASDAQ:RAPT – Get Free Report) has received a consensus rating of “Hold” from the ten analysts that are covering the company, Marketbeat Ratings reports. Nine equities research analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $18.17.
RAPT has been the topic of a number of research analyst reports. UBS Group reduced their price target on shares of RAPT Therapeutics from $10.00 to $2.00 and set a “neutral” rating on the stock in a research note on Monday, September 9th. HC Wainwright reissued a “neutral” rating on shares of RAPT Therapeutics in a research note on Tuesday, August 20th.
View Our Latest Analysis on RAPT Therapeutics
Institutional Investors Weigh In On RAPT Therapeutics
RAPT Therapeutics Price Performance
NASDAQ:RAPT opened at $1.72 on Monday. The firm has a market capitalization of $60.03 million, a price-to-earnings ratio of -0.55 and a beta of 0.33. The company’s 50-day moving average is $1.98 and its two-hundred day moving average is $3.69. RAPT Therapeutics has a 1-year low of $1.64 and a 1-year high of $27.35.
RAPT Therapeutics (NASDAQ:RAPT – Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.03. As a group, equities analysts anticipate that RAPT Therapeutics will post -2.73 earnings per share for the current fiscal year.
RAPT Therapeutics Company Profile
RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
Recommended Stories
- Five stocks we like better than RAPT Therapeutics
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- There Are Different Types of Stock To Invest In
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Dividend Capture Strategy: What You Need to Know
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for RAPT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RAPT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.